TW200615273A - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha - Google Patents
Fused tricyclic compounds as inhibitors of tumor necrosis factor-alphaInfo
- Publication number
- TW200615273A TW200615273A TW094138179A TW94138179A TW200615273A TW 200615273 A TW200615273 A TW 200615273A TW 094138179 A TW094138179 A TW 094138179A TW 94138179 A TW94138179 A TW 94138179A TW 200615273 A TW200615273 A TW 200615273A
- Authority
- TW
- Taiwan
- Prior art keywords
- inhibitors
- alpha
- necrosis factor
- tumor necrosis
- tricyclic compounds
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2004 | 2004-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200615273A true TW200615273A (en) | 2006-05-16 |
Family
ID=38654748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094138179A TW200615273A (en) | 2004-11-10 | 2005-10-31 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7834052B2 (enExample) |
| EP (1) | EP1812419A2 (enExample) |
| JP (1) | JP2008519824A (enExample) |
| KR (1) | KR20070106981A (enExample) |
| CN (1) | CN101076525B (enExample) |
| AR (1) | AR056861A1 (enExample) |
| AU (1) | AU2005303410B2 (enExample) |
| CA (1) | CA2587671A1 (enExample) |
| IL (2) | IL183038A0 (enExample) |
| MX (1) | MX2007005470A (enExample) |
| NZ (1) | NZ554937A (enExample) |
| RU (1) | RU2406724C2 (enExample) |
| TW (1) | TW200615273A (enExample) |
| WO (1) | WO2006051477A2 (enExample) |
| ZA (1) | ZA200703712B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| IN2012DN01684A (enExample) | 2009-08-27 | 2015-06-05 | U S A Represented By The Secretary Dept Of Health And Human Services | |
| WO2011075375A1 (en) * | 2009-12-14 | 2011-06-23 | Schering Corporation | Fused tricyclic compounds for the treatment of inflammatory disorders |
| JP5697685B2 (ja) * | 2009-12-18 | 2015-04-08 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 三環式抗生物質 |
| US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| GB201507903D0 (en) * | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| CN106995382A (zh) * | 2016-01-25 | 2017-08-01 | 济南和润化工科技有限公司 | 一种催化氢化法生产3-甲基-4-氨基苯甲酸的方法 |
| WO2017167993A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CA3019245A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN109219609B (zh) * | 2016-04-01 | 2022-02-01 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合六环咪唑衍生物 |
| WO2017167996A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN106831460A (zh) * | 2017-02-24 | 2017-06-13 | 青铜峡市嘉华化工有限公司 | 3‑甲基‑4‑氨基苯甲酸的制备方法 |
| USD817148S1 (en) * | 2017-04-05 | 2018-05-08 | Dormakaba Canada Inc. | Locking system housing |
| CN107501106A (zh) * | 2017-08-14 | 2017-12-22 | 中涛新材料有限公司 | 一种催化加氢制备3‑甲基‑4‑氨基苯甲酸的方法 |
| US12240855B2 (en) | 2019-03-06 | 2025-03-04 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| CN115010621B (zh) * | 2022-07-21 | 2023-11-03 | 山东百启生物医药有限公司 | 一种4-溴-3-甲基苯甲腈的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL48807A0 (en) | 1975-02-18 | 1976-03-31 | Syntex Inc | Novel 6,11-dihydrodibenzo-thiepin-11-ones,their preparation and compositions containing them |
| US4130654A (en) * | 1978-01-30 | 1978-12-19 | Syntex (U.S.A.) Inc. | Novel 4-(8X-6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof |
| IL57077A0 (en) * | 1978-04-21 | 1979-07-25 | Syntex Inc | 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them |
| GB2094790B (en) * | 1981-03-13 | 1985-10-09 | Spofa Vereinigte Pharma Werke | Tricycle compounds |
| JPH0240662A (ja) | 1988-08-01 | 1990-02-09 | Ricoh Co Ltd | 電子写真用感光体 |
| US5036067A (en) * | 1990-03-14 | 1991-07-30 | Merck & Co., Inc. | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| JPH08119920A (ja) | 1994-10-18 | 1996-05-14 | Kyowa Hakko Kogyo Co Ltd | 三環式アニリド誘導体 |
| US5698551A (en) | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
| JPH0940662A (ja) | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
| IT1283637B1 (it) * | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| JPH11130772A (ja) | 1997-10-28 | 1999-05-18 | Kyowa Hakko Kogyo Co Ltd | 含窒素複素環化合物 |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| TW200614995A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors |
-
2005
- 2005-10-31 TW TW094138179A patent/TW200615273A/zh unknown
- 2005-11-08 EP EP05801266A patent/EP1812419A2/en not_active Withdrawn
- 2005-11-08 NZ NZ554937A patent/NZ554937A/en not_active IP Right Cessation
- 2005-11-08 US US11/667,580 patent/US7834052B2/en not_active Expired - Fee Related
- 2005-11-08 CN CN2005800426605A patent/CN101076525B/zh not_active Expired - Fee Related
- 2005-11-08 AU AU2005303410A patent/AU2005303410B2/en not_active Ceased
- 2005-11-08 JP JP2007540782A patent/JP2008519824A/ja not_active Ceased
- 2005-11-08 CA CA002587671A patent/CA2587671A1/en not_active Abandoned
- 2005-11-08 KR KR1020077013140A patent/KR20070106981A/ko not_active Ceased
- 2005-11-08 WO PCT/IB2005/053654 patent/WO2006051477A2/en not_active Ceased
- 2005-11-08 RU RU2007121682/04A patent/RU2406724C2/ru not_active IP Right Cessation
- 2005-11-08 MX MX2007005470A patent/MX2007005470A/es active IP Right Grant
- 2005-11-10 AR ARP050104716A patent/AR056861A1/es not_active Application Discontinuation
-
2007
- 2007-05-07 IL IL183038A patent/IL183038A0/en not_active IP Right Cessation
- 2007-05-07 IL IL210036A patent/IL210036A0/en unknown
- 2007-05-08 ZA ZA200703712A patent/ZA200703712B/xx unknown
-
2010
- 2010-08-11 US US12/854,745 patent/US7964631B2/en not_active Expired - Fee Related
- 2010-08-11 US US12/854,761 patent/US8163730B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7834052B2 (en) | 2010-11-16 |
| CN101076525A (zh) | 2007-11-21 |
| US8163730B2 (en) | 2012-04-24 |
| AU2005303410B2 (en) | 2011-12-15 |
| EP1812419A2 (en) | 2007-08-01 |
| CN101076525B (zh) | 2011-07-27 |
| MX2007005470A (es) | 2007-07-10 |
| ZA200703712B (en) | 2010-04-28 |
| IL210036A0 (en) | 2011-02-28 |
| NZ554937A (en) | 2011-01-28 |
| WO2006051477A2 (en) | 2006-05-18 |
| US20100305094A1 (en) | 2010-12-02 |
| RU2406724C2 (ru) | 2010-12-20 |
| CA2587671A1 (en) | 2006-05-18 |
| US20100324026A1 (en) | 2010-12-23 |
| IL183038A0 (en) | 2007-09-20 |
| JP2008519824A (ja) | 2008-06-12 |
| AU2005303410A1 (en) | 2006-05-18 |
| WO2006051477A3 (en) | 2006-08-03 |
| KR20070106981A (ko) | 2007-11-06 |
| US7964631B2 (en) | 2011-06-21 |
| US20070299050A1 (en) | 2007-12-27 |
| RU2007121682A (ru) | 2008-12-20 |
| AR056861A1 (es) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007005470A (es) | Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral. | |
| NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
| DE60330150D1 (en) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| NZ507169A (en) | Aminocyclohexyl ether compounds and uses thereof | |
| WO2004013120A8 (en) | Novel benzodioxoles | |
| IL163629A0 (en) | Glutaminyl derivatives and pharmaceutical compositions containing the same | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| DE60310576D1 (en) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
| WO2001078711A3 (en) | Pde-v inhibitors for treatment of parkinson's disease | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| TW200504034A (en) | Therapeutic agents | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| TW200505920A (en) | Organic compounds | |
| WO2005028429A3 (en) | Haloalkyl containing compounds as cysteine protease inhibitors | |
| GB0323204D0 (en) | Organic compounds | |
| DE60330651D1 (en) | C3-cyanoepothilonderivate | |
| SI1701940T1 (sl) | 2-(1h-indolilsulfanil)-benzil aminski derivati kot ssri | |
| IL175819A0 (en) | Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease | |
| PL1730147T3 (pl) | Podstawowe związki 1,4,8-triazaspiro[4.5]dekan-2-onu | |
| SI1730144T1 (sl) | Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on | |
| IL173819A0 (en) | Compounds and methods for treating dyslipidemia | |
| WO2004037769A3 (en) | Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant | |
| WO2005010154A3 (en) | 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity | |
| AU2004313693A1 (en) | Diaza-spiropiperidine derivatives |